Scholarlink

Background <p>This study aimed to evaluate the safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) for the management of acute respiratory distress syndrome in critically ill patients on mechanical ventilation.</p> Methods <p>A Phase 2a/b randomised, double-blind, placebo-controlled multicentre trial was conducted. Patients with acute respiratory distress syndrome were assigned to receive PEG-ADM 960&#xa0;μg or 1920&#xa0;μg, or placebo. The primary endpoints were safety, efficacy, and ventilator-free survival at Day 28. Efficacy was assessed using ventilator-free survival and the clinical utility index, a composite endpoint that includes extravascular lung water index, oxygenation index, non-pulmonary Sequential Organ Failure Assessment score.</p> Results <p>Ninety patients were randomised (PEG-ADM 960&#xa0;μg: n = 29; PEG-ADM 1920&#xa0;μg: n = 30; placebo: n = 31). Both dosages of PEG-ADM were well tolerated, with adverse event profiles similar to placebo. However, no significant efficacy was observed on the clinical utility index. Ventilator-free survival at Day 28 was lower in the PEG-ADM 960&#xa0;μg group (52%) compared with the PEG-ADM 1920&#xa0;μg (67%) and placebo (65%) groups. No significant differences were noted in overall mortality or the need for continued ventilation at Days 28 and 60.</p> Conclusion <p>Inhaled PEG-ADM was well tolerated in patients with acute respiratory distress syndrome, but it did not improve clinical outcomes, which led to the early discontinuation after the first part of the trial for futility.</p> Trial registration <p>ClinicalTrials.gov: NCT04417036 (date of registration: 4 June 2020).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of inhaled PEG-ADM in ARDS patients: a randomised controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Christian Karagiannidis,
  • Danny F. McAuley,
  • B. Taylor Thompson,
  • Thomas Reimer,
  • Kaweh Shakery,
  • Sebastian Schmitz,
  • Manuel Núñez Cortés,
  • Roman Ullrich,
  • Ferhat Meziani,
  • Alain Mercat,
  • Davide Chiumello,
  • Frantisek Duska,
  • Alain Combes,
  • Christian Karagiannidis,
  • Danny F. McAuley,
  • B. Taylor Thompson,
  • Thomas Reimer,
  • Kaweh Shakery,
  • Sebastian Schmitz,
  • Manuel Núñez Cortés,
  • Roman Ullrich,
  • Ferhat Meziani,
  • Alain Mercat,
  • Davide Chiumello,
  • Frantisek Duska,
  • Alain Combes,
  • Katharina Krenn,
  • Philipp Eller,
  • Michael Joannidis,
  • Michael Joannidis,
  • Herbert Koinig,
  • Roman Skulec,
  • Vladimir Cerny,
  • Jan Berousek,
  • Frédéric Pene,
  • Jean-Daneil Chiche,
  • Laurent Papazian,
  • Sami Hraiech,
  • Nicolas Terzi,
  • Ulf Günther,
  • Tobias Welte,
  • Martin Witzenrath,
  • Norbert Weiler,
  • Marc Berger,
  • Giacomo Grasselli,
  • Antoni Betbese Roig,
  • Candelaria de Haro Lopez,
  • Ana Ochagavia Calvo,
  • Ricardo Ferrer Roca,
  • Rafael Mañez Mendiluce,
  • Jeremy Bewley,
  • Andrew Aswani,
  • Ingeborg Welters,
  • Matthew Wise,
  • Robert Jackson

摘要

Background

This study aimed to evaluate the safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) for the management of acute respiratory distress syndrome in critically ill patients on mechanical ventilation.

Methods

A Phase 2a/b randomised, double-blind, placebo-controlled multicentre trial was conducted. Patients with acute respiratory distress syndrome were assigned to receive PEG-ADM 960 μg or 1920 μg, or placebo. The primary endpoints were safety, efficacy, and ventilator-free survival at Day 28. Efficacy was assessed using ventilator-free survival and the clinical utility index, a composite endpoint that includes extravascular lung water index, oxygenation index, non-pulmonary Sequential Organ Failure Assessment score.

Results

Ninety patients were randomised (PEG-ADM 960 μg: n = 29; PEG-ADM 1920 μg: n = 30; placebo: n = 31). Both dosages of PEG-ADM were well tolerated, with adverse event profiles similar to placebo. However, no significant efficacy was observed on the clinical utility index. Ventilator-free survival at Day 28 was lower in the PEG-ADM 960 μg group (52%) compared with the PEG-ADM 1920 μg (67%) and placebo (65%) groups. No significant differences were noted in overall mortality or the need for continued ventilation at Days 28 and 60.

Conclusion

Inhaled PEG-ADM was well tolerated in patients with acute respiratory distress syndrome, but it did not improve clinical outcomes, which led to the early discontinuation after the first part of the trial for futility.

Trial registration

ClinicalTrials.gov: NCT04417036 (date of registration: 4 June 2020).